Island Pharmaceuticals (ASX:ILA) has strengthened its position in the United States biodefence research network through a new collaborative agreement aimed at accelerating the development of its antiviral drug candidate, Galidesivir, for the treatment of Marburg virus disease.
The company announced it has entered a Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation, two organisations central to the United States’ medical countermeasure programs against biological threats.
The partnership brings together Island’s clinical-stage antiviral compound, USAMRIID’s high-containment infectious disease expertise, and Geneva’s experience in managing government-sponsored research programs. USAMRIID is the US military’s leading institute for the study of dangerous pathogens and operates one of the few laboratories capable of safely handling viruses that require the highest biosafety controls.
Under the three-year agreement, the organisations will design and conduct non-human primate studies intended to generate the data required for regulatory approval under the US Food and Drug Administration’s Animal Rule pathway. This regulatory mechanism allows treatments for rare or dangerous pathogens to be approved based on animal efficacy data when traditional human trials are not feasible.
Galidesivir has already shown promising antiviral activity in previous studies involving Ebola and Marburg infections in primates. By formalising collaboration with long-standing research partners, Island aims to accelerate the final development stages while aligning the program more closely with US government biodefence priorities. The company believes this alignment could help position Galidesivir as both a clinical solution for emerging viral threats and a strategic asset within national security preparedness efforts.